Micafungin Mylan

Micafungin, the active ingredient in Micafungin Mylan, is an echinocandin presented as an intravenous injection for intravenous use. It is indicated for the treatment of invasive candidiasis, esophageal candidiasis, and for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation and has demonstrated activity against a broad range of Candida species.

GNH USA supplies Micafungin Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide with a focus on quality and regulatory compliance.

Micafungin is an echinocandin antifungal that targets the fungal cell wall. - Invasive candidiasis: effective treatment that clears bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: resolves mucosal infection and alleviates associated pain and dysphagia. - Prophylaxis in hematopoietic stem cell transplantation: prevents Candida infection during periods of severe immunosuppression.

Micafungin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature. - Nausea: mild to moderate sensation of stomach upset. - Headache: occasional mild headache. - Elevated liver enzymes: mild increase in ALT or AST. - Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury with jaundice. - Severe hypersensitivity: anaphylaxis or angioedema. - Nephrotoxicity: acute kidney injury. - Hematologic abnormalities: thrombocytopenia or neutropenia. - Infusion‑related reactions: hypotension or bronchospasm.

When using Micafungin, clinicians should consider several precautionary measures to ensure patient safety. - Renal function: assess baseline kidney function and monitor during therapy. - Hepatic function: evaluate liver enzymes before initiation and periodically thereafter. - Drug hypersensitivity: discontinue if signs of severe allergic reaction appear. - Concomitant antifungals: avoid concurrent use with other echinocandins or agents that may increase toxicity. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Cyclosporine: increased micafungin exposure may raise toxicity risk. - Rifampin: strong enzyme induction may markedly reduce micafungin levels.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may alter plasma concentrations. - Warfarin: potential for altered anticoagulant effect; monitor INR. - Immunosuppressants (e.g., tacrolimus): monitor drug levels for possible changes. - Statins: observe for increased risk of myopathy.